The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012
Nikki Turner, Nevil Pierse, Ange Bissielo, Q Sue Huang, Michael G Baker, Marc-Alain Widdowson, Heath Kelly
Vaccine | ELSEVIER SCI LTD | Published : 2014
BACKGROUND: Few studies report the effectiveness of trivalent inactivated influenza vaccine (TIV) in preventing hospitalisation for influenza-confirmed respiratory infections. Using a prospective surveillance platform, this study reports the first such estimate from a well-defined ethnically diverse population in New Zealand (NZ). METHODS: A case test-negative design was used to estimate propensity adjusted vaccine effectiveness. Patients with a severe acute respiratory infection (SARI), defined as a patient of any age requiring hospitalisation with a history of a fever or a measured temperature ≥38°C and cough and onset within the past 7 days, admitted to public hospitals in South and Centr..View full abstract
Awarded by U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC)
Awarded by NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES
Awarded by National Center for Immunization and Respiratory Diseases (NCIRD)
The SHIVERS (Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance) project is funded by U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC) (1U01IP000480-01). The SARI surveillance is a key component of the SHIVERS project. The project is a five year research cooperative agreement between Institute of Environmental Science and Research and US CDC's National Center for Immunization and Respiratory Diseases (NCIRD) Influenza Division. The SHIVERS project is a multi-centre and multi-disciplinary collaboration. Special thanks go to these collaborating organisations for their commitment and supports: ESR, Auckland District Health Board, Counties Manukau District Health Board, University of Otago, University of Auckland, the US Centres for Disease Control and Prevention and WHO Collaborating Centre at St Jude Children's Hospital in Memphis, USA.